Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 450-453

  Fukuda, Tsuyoshi ^a   Yamamoto, Isamu ^a   Nishida, Yuko ^a   Zhou, Qian ^a   Ohno, Masako ^a   Takada, Kanji ^b   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

CYP2D6*10 genotype; Pharmacokinetics; Venlafaxine

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DESVENLAFAXINE; DRUG METABOLITE; ENDONUCLEASE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; CYTOCHROME P450 2D6;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENETIC POLYMORPHISM; GENETICS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 0032587641     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00913.x     Document Type: Article

References (17)

1. 1 Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-558.
2. 2 Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subject: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
3. 3 Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3: 256-263.
4. 4 Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994; 4: 73-81.
5. 5 Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53: 410-418.
6. 6 Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman SM. Genetic analysis of the Chinese Cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
7. 7 Daly AK, Brockmöller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
8. 8 Dahl ML, Yue QY, Roh HK, et al. Genetic analysis of the CYP2D) locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5: 159-164.
9. 9 Roh HK, Dahl ML, Johansson I, Sundberg MI, Cha YN, Bertilsson L. Debrisoquine and S-mephnytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-447.
10. 10 Ellingrod VL., Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51: 3033-3046.
11. 11 Otton SV, Ball SE, Cheung SW, Inaha T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br j Clin Pharmacol 1996; 41: 149-156.
12. 12 Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
13. 13 Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450HD6 mutant gene associated with Parkinson's disease. J Biochem Tokyo 1993; 114: 263-266.
14. 14 Steen VM, Andreasson OA, Daly AK, et al. Detection of poor metabolizer associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
15. 15 Howell SR, Husbands GEM, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus, monkey and man. Xenobiotica 1993; 23: 349-359.
16. 16 Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995; 58: 264-268.
17. 17 Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996; 60: 177-182.